Social network
Media - Staying connected to our latest news and events
Media - Staying connected to our latest news and events


Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):


Middle area:

Press releases 2007

Press releases are intended to journalists, analysts and investors.

Taxotere®-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy In Early Stage Breast Cancer

December 13, 2007

New anti-thrombotic compound AVE5026 shows highly significant dose response in TREK phase IIb study

December 10, 2007

Sanofi-aventis inaugurates first Asian development centre for pharmaceuticals in Goa, India

December 03, 2007

Sanofi-aventis and Astellas to restructure the joint venture activities in Japan of Fujisawa sanofi-aventis K.K.

November 30, 2007

Sanofi-aventis initiates a major global collaboration with Regeneron to develop and commercialize fully-human therapeutic antibodies and plans to increase its stake in Regeneron to approximately 19 %

November 29, 2007

Sanofi-aventis to build a vaccine facility in Shenzhen for prevention of influenza and pandemic readiness in China

November 26, 2007

Rimonabant - Bibliographical update

November 16, 2007

Rimonabant - Regulatory Update in Europe

November 13, 2007

Sanofi Pasteur and Acambis join forces to bring West Nile vaccine to market

November 13, 2007

New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort® AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis

November 10, 2007

Retrospective Analysis Finds that Initiation of Insulin Glargine in Patients with Type 2 Diabetes was Associated with a Lower Incidence Rate of Myocardial Infarction as Compared with NPH Insulin

November 07, 2007

Coarsucam™/“ASAQ” is as Effective as Coartem® in Treating Uncomplicated Malaria

November 07, 2007

Sanofi Pasteur initiates phase II trial of cell culture-based seasonal influenza vaccine

November 07, 2007

Sanofi Pasteur presents positive results of tetravalent dengue candidate vaccine

November 06, 2007

Good third quarter performance: increase in 2007 full-year earnings growth guidance

October 31, 2007

Studies Showing Significant Survival Improvement with Taxotere®-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of The New England Journal of Medicine

October 24, 2007

New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR® (zolpidem tartrate extended-release) tablets

October 24, 2007

Taxotere® receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval in the European Union for induction treatment for locally advanced Head and Neck cancer

October 22, 2007

Plavix® indications expanded in Japan to include patients with Acute Coronary Syndrome for whom percutaneous coronary intervention is being planned

October 22, 2007

Sanofi Pasteur receives FDA approval of meningococcal vaccine for children

October 18, 2007

Sanofi Pasteur and Institut Pasteur team up against malaria

October 15, 2007

New prescription allergy treatment XYZAL® (levocetirizine dihydrochloride) now available for fall allergy season in the USA

October 02, 2007

Taxotere® (docetaxel) granted FDA approval to treat Locally Advanced Head and Neck Cancer prior to chemoradiotherapy and surgery

October 01, 2007

Sanofi-aventis enters the Dow Jones Sustainability World Indexes (DJSI World)

September 24, 2007

Appropriate glycemic control contributes to reducing the risk of macrovascular diseases in patients with diabetes

September 19, 2007

Rimonabant effectively reduces visceral fat in the obese patient as confirmed by abdominal computer tomography (CT) scan

September 19, 2007

A promising R&D portfolio, well positioned to deliver future growth

September 17, 2007

Sanofi-aventis initiates Research collaboration in China in the cancer stem-cell field

September 14, 2007

Sanofi-aventis announces settlement of Average Wholesale Price Civil Suits with the U.S. Department of Justice relating to Anzemet®

September 10, 2007

The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With No Observed Pro-Arrhythmia

September 05, 2007

Survival Benefit of Taxotere®-Based Regimens In Patients With Non Small Cell Lung Cancer

September 04, 2007

New Study Findings Confirm CLEXANE®/LOVENOX® Long-Term Clinical Benefit In Patients Suffering From Acute Coronary Syndrome

September 03, 2007

Availability on line of the Group’s half-year financial report for 2007

August 02, 2007

First half: solid results in a difficult context. Plavix® recovers its position in the US, full impact expected in H2

August 01, 2007

Sanofi pasteur President and CEO David J. Williams to retire; Wayne Pisano named President and CEO

July 26, 2007

Sanofi Pasteur announces completion of construction of new U.S. influenza vaccine manufacturing facility

July 20, 2007

CHMP approves labelling update of Acomplia® in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression

July 19, 2007

Idraparinux shows encouraging results in the prevention of thromboembolic events in patients with atrial fibrillation

July 11, 2007

New study shows that extending prophylaxis with Clexane®/ Lovenox® (enoxaparin sodium injection) to 5 weeks is more effective than 10 days for reducing the risk of venous thromboembolism (VTE) in acutely ill medical patients with reduced mobility

July 08, 2007

Plavix® (clopidogrel bisulfate) receives priority review in Japan for supplemental new drug application (sNDA) for The treatment of acute coronary syndrome

July 04, 2007

Rimonabant Regulatory Update in the United States

June 29, 2007

Rimonabant Regulatory Update in Europe

June 29, 2007

Taxotere® (docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery

June 27, 2007

Apidra® Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin And Oral Antidiabetic Treatments (BOT)

June 24, 2007

For any given level of HbA1c, Lantus® demonstrates less confirmed hypoglycemia over Insulin NPH

June 23, 2007

Results of Two Head-to-Head Studies Demonstrated Long-Acting Insulin Lantus® Lowered Free Fatty Acid Levels Equal to or Better Than Thiazolidinediones

June 23, 2007

Sanofi-aventis and Bristol-Myers Squibb Prevail in U.S. Plavix® Patent Litigation

June 19, 2007

Sanofi pasteur awarded contract to retrofit influenza vaccine facility

June 14, 2007

FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factors

June 13, 2007

Sanofi pasteur supports WHO initiative for the establishment of an H5N1 vaccine stockpile

June 13, 2007

Taxotere® (docetaxel) receives Priority Review in Japan for Supplemental New Drug Application (sNDA) in prostate cancer

June 07, 2007

Sanofi-aventis at the 43rd annual 2007 ASCO meeting

June 06, 2007

Copaxone® pre-filled syringe can now be stored for up to one month at room temperature

June 06, 2007

Eloxatin® (oxaliplatin injection)-based chemotherapy sets new treatment benchmark in patients with metastatic colorectal cancer

June 04, 2007

The Eloxatin®-based regimen (FOLFOX4) significantly improved progression free survival when given before and after surgery in patients with resectable liver metastases from colorectal cancer

June 04, 2007

Oxford BioMedica and Sanofi-aventis report encouraging new TroVax® phase II trial results in renal cancer

June 03, 2007

S-1, a novel oral fluoropyrimidine, when combined with cisplatin, demonstrates significant improvement in overall survival of advanced gastric cancer patients over S-1 alone

June 03, 2007

FOLFOX4 (Eloxatin®-based chemotherapy) after surgery improves overall survival in patients with early (stage III) colon cancer

June 03, 2007

“My child matters” one-year report program shows measurable improvement in cancer care for children in developing and newly industrialized countries

June 03, 2007

Encouraging results of VEGF Trap (Aflibercept) highlighted at ASCO 2007 annual meeting

June 02, 2007

Annual General Meeting

May 31, 2007

FDA approves XYZAL® tablets for the treatment of seasonal and year round allergies, and chronic urticaria

May 29, 2007

Data to be presented at ASCO 2007 highlights sanofi-aventis commitment to oncology

May 25, 2007

FDA approves Lovenox® (Enoxaparin Sodium Injection) for the most severe type of heart attack

May 18, 2007

Sanofi-aventis calls for an effective policy against drug counterfeiting

May 15, 2007

Full-year guidance raised on good 2007 first-quarter results

May 03, 2007

FDA Approves SoloSTAR® - A New Prefilled Disposable Insulin Pen For Use With LANTUS® In People With Type 1 And Type 2 Diabetes

April 30, 2007

Information relating to sanofi-aventis’ Combined General Meeting of May 31, 2007

April 26, 2007

Acomplia® (rimonabant) is approved in Brazil for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidemia

April 26, 2007

ACOMPLIA® (rimonabant) is reimbursed in Switzerland for the treatment of Type 2 Diabetics Overweight Patients and for the treatment of Patients with Obesity

April 24, 2007

The Lancet Publishes PREVAIL Study Results Showing Lovenox® Superiority Over Unfractionated Heparin For Reducing The Risk Of Venous Thromboembolism In Patients With Acute Ischemic Stroke

April 20, 2007

FDA Licenses First U.S. Vaccine for Humans Against Avian Influenza

April 17, 2007

Filing of the 2006 U.S. Form 20-F and French "Document de Référence"

April 03, 2007

Acomplia® (rimonabant) approved in Switzerland for the treatment of obese and overweight patients with at least one cardiovascular risk factor

April 03, 2007

Panaldine® commercial rights transferred from Daiichi to sanofi-aventis in Japan

April 02, 2007

Sanofi-aventis Announces Update To The European Summary Of Product Characteristics (SmPC) For Ketek® (telithromycin)

March 30, 2007

Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For Cancer

March 28, 2007

Rimonabant USA: Update

March 26, 2007

Acomplia® (rimonabant) is now officially reimbursable in France, for the treatment of eligible obese and Type 2 diabetic patients

March 22, 2007

LANTUS®SoloSTAR® and APIDRA®SoloSTAR® – New Disposable Insulin Pens for People with Type 1 and Type 2 Diabetes Will Be Launched Starting April 2007 in Europe

March 16, 2007

Sanofi-aventis' commitment to providing "Access to Medicines" in countries in the Southern Hemisphere shows real achievements

March 12, 2007

New, Once-a-Day Fixed-Dose Combination Against Malaria Now Available

March 01, 2007

Taxotere® (docetaxel) significantly improves the survival of patients with advanced prostate cancer

February 23, 2007

Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine from Acambis

February 14, 2007

2006: In a difficult environment, another year of growth in adjusted EPS excluding selected items

February 13, 2007

Rimonabant USA: Update

February 12, 2007

Sanofi-aventis announces update to US Prescribing Information for Ketek® (telithromycin)

February 12, 2007

LOVENOX® patent infringement suit decided against Sanofi-aventis

February 09, 2007

FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack

February 06, 2007

Positive Recommendation for Acomplia® from the Transparency Committee in France

February 06, 2007

"My child matters": 26 programmes launched in 16 countries to fight childhood cancers

February 01, 2007

FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine

January 25, 2007

S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery alone

January 19, 2007

Sanofi-aventis intends to contest in court the decision to classify Acomplia® among non-reimbursable drugs in Germany

January 12, 2007

New Head of Research & Development at sanofi-aventis

January 05, 2007

Right area:




Filter by date


© Sanofi 2004-2016 - All rights reserved - Update: March 12, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)